Survival Predictors of Head and Neck Burkitt's Lymphoma: An Analysis of the SEER Database. (July 2022)

• Record Type: Journal Article
• Authors: Ahsanuddin, Salma; Cadwell, Joshua B.; Sangal, Neel R.; Grube, Jordon G.; Fang, Christina H.; Baredes, Soly; Eloy, Jean Anderson
• Is Part Of: Otolaryngology--head and neck surgery. Volume 167:Number 1(2022)
• Page Start: 79
• Page End: 88
• Publication Date: 2022-07
• Subjects: head and neck -- survival -- otolaryngology -- nationwide -- lymphoma; Head -- Surgery -- Periodicals; Neck -- Surgery -- Periodicals; Otolaryngology -- Periodicals; 617.51
• DOI: 10.1177/01945998211041533
• Languages: English
• ISSNs: 0194-5998

Abstract

Objective: To analyze population-level data for Burkitt's lymphoma of the head and neck. Study Design: Retrospective study of a national cancer database. Setting: Academic medical center. Methods: The SEER database (Surveillance, Epidemiology, and End Results) identified all patients with primary Burkitt's lymphoma of the head and neck from 1975 to 2015. Demographic, clinicopathologic, and treatment characteristics were analyzed. Multivariable Cox regressions analyzed factors associated with survival while controlling for baseline differences. Results: A total of 920 patients with a mean (SD) age of 37.6 years (25.0) were identified. A majority of patients were White (82.8%) and male (72.3%). The most primary common sites included the lymph nodes (61.3%), pharynx (17.7%), and nasal cavity/paranasal sinuses (5.2%). The majority of patients received chemotherapy (90.5%), while fewer underwent surgery (42.1%) or radiotherapy (12.8%). Choice of treatment differed significantly among patients of different ages, year of diagnosis, primary site, nodal status, and Ann Arbor stage. Overall 10-year survival was 67.8%. On multivariable Cox regression, patients with older age (hazard ratio [HR], 1.05 per year; P < .001) and higher stage at presentation had increased risk of mortality ( P < .001). Furthermore, cases diagnosed between 2006 and 2015 (HR, 0.35; P < .001) and 1996 and 2005 (HR, 0.53; P = .001) had lower mortality when compared with those diagnosed between 1975 and 1995. Treatment including surgery and chemotherapy tended to have the best survival ( P < .001). Conclusion: Burkitt's lymphoma of the head and neck diagnosed in more recent years has had improved survival. Factors significantly associated with survival include age, Ann Arbor stage, and treatment regimen. Treatment including surgery and chemotherapy was associated with the highest survival.